As filed with the Securities and Exchange Commission on July 10, 2008

Registration No. 333-

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM S-8

 

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

REGENERX BIOPHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

(State or other jurisdiction of

incorporation or organization)

 

52-1253406

(I.R.S. Employer Identification No.)

 

3 Bethesda Metro Center, Suite 700, Bethesda, MD

 

20814

(Address of registrant’s principal executive offices)

 

(Zip Code)

 

RegeneRx Biopharmaceuticals, Inc. Amended and Restated 2000 Stock Option and Incentive Plan

(Full title of the Plan)

 

J.J. Finkelstein

President and Chief Executive Officer

RegeneRx Biopharmaceuticals, Inc.

3 Bethesda Metro Center, Suite 700

Bethesda, MD 20814

(Name and address of agent for service)

 

(301) 961-1992

(Telephone number, including area code, of agent for service)

 

Copy to:

Darren K. DeStefano, Esq.

Cooley Godward Kronish LLP

11951 Freedom Drive

Reston, VA 20190-5656

(703) 456-8000

 

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company (as defined in Rule 12b-2 of the Act).

 

Large accelerated filer o     Accelerated filer o     Non-accelerated filer o     Smaller reporting company x

 

CALCULATION OF REGISTRATION FEE

 

Title of securities to be registered

 

Amount
to be
registered (1)

 

Proposed maximum
offering price
per share (2)

 

Proposed maximum
aggregate offering
price

 

Amount of
registration
fee

Common Stock, par value $0.001 per share

 

4,000,000

 

$

1.26

 

$

5,040,000

 

$

197.26

(1)            Pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement also covers an indeterminate number of additional shares that may be issuable in connection with share splits, share dividends or similar transactions.

 

(2)            Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and (h) under the Securities Act, based upon the average of the high and low prices of the Registrant’s Common Stock for July 7, 2008 as reported on the American Stock Exchange.

 

 



 

EXPLANATORY NOTE

 

This registration statement (the “Registration Statement”) is being filed by RegeneRx Biopharmaceuticals, Inc. (the “Company,” “we,” “us” and “our”) for the purpose of registering an additional 4,000,000 shares of our common stock (the “Common Stock”) reserved for issuance upon the exercise of stock awards granted or available for grant under the RegeneRx Biopharmaceuticals, Inc. Amended and Restated 2000 Stock Option and Incentive Plan, as amended (the “Plan”).  On December 19, 2003, we filed with the Securities and Exchange Commission (the “Commission”) an effective registration statement of Form S-8 (File No. 333-111386) covering the issuance of up to 2,500,000 shares of Common Stock under the Plan.

 

PART I

 

INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTU S

 

Item 1.                     Plan Information*

 

Item 2.                     Registrant Information and Employee Plan Annual Information*

 

* Information required by Part I to be contained in the Section 10(a) prospectus is omitted from this Registration Statement in accordance with Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”) and the Note to Part I of Form S-8.

 

PART II

 

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

 

Item 3.                     Incorporation of Documents by Reference.

 

The following documents, which have heretofore been filed by us with the Commission pursuant to the Securities Act and pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are incorporated by reference herein and shall be deemed to be a part hereof:

 

(1)

Our Annual Report on Form 10-K for the fiscal year ended December 31, 2007, filed on March 28, 2008, as amended by our report on Form 10-K/A, filed on April 4, 2008; and

 

 

(2)

Our Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2008, filed on May 15, 2008; and

 

 

(3)

Our Current Reports on Form 8-K filed on January 7, 2008, February 27, 2008, April 1, 2008 (other than information furnished pursuant to Items 2.02, 7.01 and 9.01 thereof), April 4, 2008 (other than information furnished pursuant to Items 2.02 thereof), July 2, 2008 (other than information furnished pursuant to Item 7.01 thereof) and July 9, 2008.

 

 

(4)

The description of our Common Stock contained in our registration statement on Form S-3 filed on May 6, 2008 (File No. 333-150675) and all amendments or reports filed for the purpose of updating such description.

 

All documents later filed by us under Sections 13(a), 13(c), 14 or 15(d) of the Securities Act, before we file a post-effective amendment to this Registration Statement that indicates all securities offered hereby have been sold or which deregisters all such securities that have not been sold, shall be deemed to be incorporated by reference and be a part of this Registration Statement from the date that document was filed.

 

Any statement contained herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed incorporated document modifies or supersedes such statement. Any statement contained in an incorporated document shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed incorporated document modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

 

The Registrant’s Exchange Act file number with the Commission is 001-15070

 

Item 4.                     Description of Securities.

 

Not applicable.

 

Item 5.                     Interests of Named Experts and Counsel.

 

Not applicable.

 

2



 

Item 6.                     Indemnification of Directors and Officers.

 

Section 145 of the Delaware General Corporation Law provides that a corporation may indemnify directors and officers as well as other employees and individuals against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with any threatened, pending or completed actions, suits or proceedings in which such person is made a party by reason of such person being or having been a director, officer, employee of or agent to the Company. The statute provides that it is not exclusive of other rights to which those seeking indemnification may be entitled under any by-law, agreement, vote of stockholders or disinterested directors or otherwise.

 

Article VII of the Company’s bylaws provides that the Company shall indemnify any person who was or is a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the Corporation) by reason of the fact that he is or was a director, officer, employee or agent of the Company, or is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise (all such persons being referred to hereinafter as an “Indemnitee”), against expenses (including attorneys’ fees), judgments, fines, and amounts paid in settlement actually and reasonably incurred by him in connection with such action, suit, or proceeding if he acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the Company, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful. The termination of any action, suit or proceeding by judgment, order, settlement, conviction, or upon a plea of nolo contendere or its equivalent, shall not, or itself, create a presumption that the person did not act in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, that such person had reasonable cause to believe that his conduct was unlawful.

 

Section 102(b)(7) of the Delaware General Corporation Law permits a corporation to provide in its certificate of incorporation that a director of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability (i) for any breach of the director’s duty of loyalty to the corporation or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) for payments of unlawful dividends or unlawful stock repurchases or redemptions, or (iv) for any transaction from which the director derived an improper personal benefit. The Company’s certificate of incorporation provides for such limitation of liability.

 

Section 145 further authorizes a corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation or enterprise, against any liability asserted against him and incurred by him in any such capacity, arising out of his status as such, whether or not the corporation would otherwise have the power to indemnify him under Section 145. Policies of insurance are maintained by the Company under which its directors and officers are insured, within the limits and subject to the limitations of the policies, against certain expenses in connection with the defense of, and certain liabilities which might be imposed as result of, actions, suits or proceedings to which they are parties by reason of being or having been such directors or officers.

 

Item 7.                     Exemption from Registration Claimed.

 

Not applicable.

 

Item 8.                     Exhibits.

 

See Exhibit Index.

 

Item 9.                     Undertakings .

 

(a) The undersigned registrant hereby undertakes:

 

(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

 

(i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

 

(ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and

 

(iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

 

provided , however , that the undertakings set forth in clauses (i) and (ii) above do not apply if the information required to be included in a post-effective amendment by those clauses is contained in periodic reports filed with or furnished to the SEC by the registrant

 

3



 

pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that are incorporated by reference in this registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement.

 

(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new Registration Statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

 

(3) To remove from the registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

 

(4) That, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act that is incorporated by reference in this registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

 

(5) That, insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

 

4



 

SIGNATURES

 

The Registrant.  Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Bethesda, State of Maryland on this 10th day July, 2008.

 

 

REGENERX BIOPHARMACEUTICALS, INC.

 

 

 

By:

/s/ J.J. FINKELSTEIN

 

 

J.J. Finkelstein

 

 

President, Chief Executive Officer and Director

 

 

POWER OF ATTORNEY

 

KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Allan L. Goldstein or J.J. Finkelstein as his or her true and lawful attorney-in-fact and agent, with power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any amendments to this Registration Statement, and to file the same, with all exhibits and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their, his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

 

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities indicated on this 10th day July, 2008.

 

Signature

 

Title

 

Date

 

 

 

 

 

 

 

 

 

 

/s/ ALLAN L. GOLDSTEIN

 

Chairman of the Board, Chief Scientific Advisor and Director

 

July 10, 2008

Allan L. Goldstein

 

 

 

 

 

 

 

 

 

/s/ J.J. FINKELSTEIN

 

President, Chief Executive Officer and Director

 

July 10, 2008

J.J. Finkelstein

 

(Principal Executive Officer)

 

 

 

 

 

 

 

/s/ RICHARD J. HINDIN

 

Secretary and Director

 

July 10, 2008

Richard J. Hindin

 

 

 

 

 

 

 

 

 

/s/ JOSEPH C. MCNAY

 

Director

 

July 10, 2008

Joseph C. McNay

 

 

 

 

 

 

 

 

 

/s/ L. THOMPSON BOWLES

 

Director

 

July 10, 2008

L. Thompson Bowles

 

 

 

 

 

 

 

 

 

 

 

Director

 

 

Mauro Bove

 

 

 

 

 

 

 

 

 

/s/ C. NEIL LYONS

 

Chief Financial Officer and Treasurer

 

July 10, 2008

C. Neil Lyons

 

(Principal Financial and Accounting Officer)

 

 

 

5



 

EXHIBIT INDEX

 

Exhibit
No.

 

Description

3.1

 

Restated Certificate of Incorporation of the Company

 

Exhibit 3.1 to the Company’s Registration Statement No. 33-9370, Amendment No. 1 (filed November 26, 1986)

 

 

 

 

 

3.2

 

Certificate of Amendment

 

Exhibit 3.2 to the Company’s Transitional Report on Form 10-K (filed March 18, 1991)

 

 

 

 

 

3.3

 

Certificate of Amendment

 

Exhibit 3.3 to the Company’s Annual Report on Form 10-KSB (filed April 2, 2001)

 

 

 

 

 

3.4

 

Form of Certificate of Designation of Series A Participating Cumulative Preferred Stock

 

Exhibit 2 to the Company’s Current Report on Form 8-K (filed May 2, 1994)

 

 

 

 

 

3.5

 

Amended and Restated Bylaws of the Company

 

Exhibit 3.4 to the Company’s Quarterly Report on Form 10-Q (filed August 14, 2006)

 

 

 

 

 

3.6

 

Amendment to Amended and Restated Bylaws of the Company

 

Filed herewith

 

 

 

 

 

4.1

 

Form of Stock Certificate

 

Exhibit 4.1 to the Company’s Registration Statement No. 33–9370, Amendment No. 1 (filed November 26, 1986)

 

 

 

 

 

4.2

 

Form of Rights Certificate

 

Exhibit 3 to the Company’s Current Report on Form 8-K (filed May 2, 1994)

 

 

 

 

 

4.3

 

Rights Agreement, dated as of April 29, 1994, between the Company and American Stock Transfer & Trust Company, as Rights Agent

 

Exhibit 1 to the Company’s Current Report on Form 8-K (filed May 2, 1994)

 

 

 

 

 

4.4

 

Amendment No. 1 to Rights Agreement, dated March 4, 2004, between the Company and American Stock Transfer & Trust Company, as Rights Agent

 

Exhibit 4.3 to the Company’s Annual Report on Form 10-KSB (filed March 31, 2006)

 

 

 

 

 

5.1

 

Opinion of Cooley Godward Kronish LLP

 

Filed herewith

 

 

 

 

 

23.1

 

Consent of Independent Registered Public Accounting Firm

 

Filed herewith

 

 

 

 

 

23.1

 

Consent of Cooley Godward Kronish LLP

 

Included in Exhibit 5.1

 

 

 

 

 

24.1

 

Power of Attorney

 

Included on signature page

 

 

 

 

 

99.1

 

RegeneRx Biopharmaceuticals, Inc. Amended and Restated 2000 Stock Option and Incentive Plan

 

Exhibit A to the Company’s Proxy Statement on Schedule 14A (filed May 9, 2008)

 

6


Exhibit 3.6

 

Section 5.1 of Article V of the Company’s Amended and Restated Bylaws (amended to add the words “, or may be in uncertificated form,” as set forth below):

 

Section 5.1     Stock Certificates.   Certificates representing shares of stock of the Corporation shall be in such form , or may be in uncertificated form, consistent with all applicable provisions of law, as shall be approved by the Board of Directors. All certificates shall be signed in the name of the Corporation by the Chairman of the Board of Directors, the President or a Vice President and by the Treasurer or an Assistant Treasurer or the Secretary or an Assistant Secretary, and may be sealed with the seal of the Corporation or facsimile thereof.  If a certificate is countersigned (1) by a transfer agent other than the Corporation or its employee, or (2) by a registrar other than the Corporation or its employee, any signature of an officer of the Corporation may be facsimile.  If any officer, transfer agent or registrar who has signed or whose facsimile signature has been placed upon such certificate shall have ceased to be such officer, transfer agent or registrar before such certificate is issued, it may be issued by the Corporation with the same effect as if he were such officer, transfer agent or registrar at the date of its issue.

 


Exhibit 5.1

 

[Cooley Godward Kronish LLP Letterhead]

 

July 10, 2008

 

RegeneRx Pharmaceuticals, Inc.

3 Bethesda Metro Center, Suite 630

Bethesda, MD 20814

 

Ladies and Gentlemen:

 

You have requested our opinion with respect to certain matters in connection with the filing by RegeneRx Biopharmaceuticals, Inc., a Delaware corporation (the “ Company ”), of a Registration Statement on Form S-8 (the “ Registration Statement ”) with the U.S. Securities and Exchange Commission covering the offering of up to four million (4,000,000) shares of common stock, par value $0.001 per share (“ 2000 Plan Shares ”), pursuant to the Company’s Amended and Restated 2000 Stock Option and Incentive Plan, as amended (the “ 2000 Plan ”).  All of the 2000 Plan Shares are to be sold by the Company as described in the Registration Statement, and related prospectus (the “ Prospectus ”).

 

In connection with this opinion, we have examined and relied upon (a) an executed copy of the Registration Statement and related Prospectus, (b) the 2000 Plan, (c) the Company’s Restated Certificate of Incorporation, as filed with the Delaware Secretary of State on November 12, 1986, as currently in effect and certified by the Secretary of the Company as being complete, accurate and correct, (d) the Company’s Amended and Restated Bylaws, as currently in effect and certified by the Secretary of the Company as being complete, accurate and correct, (e) resolutions of the Board of Directors of the Company adopted on April 21, 2004 and June 23, 2004, as certified by the Secretary of the Company as being complete, accurate, and in effect, relating to, among other things, the adoption and approval of an amendment to the 2000 Plan increasing the shares available for issuance and sale thereunder from an aggregate of two million five-hundred thousand (2,500,000) to an aggregate of three million two-hundred thousand (3,200,000) and any arrangements in connection therewith, (f) resolutions of the Board of Directors of the Company adopted on May 26, 2006, and July 26, 2006, as certified by the Secretary of the Company as being complete, accurate, and in effect, relating to, among other things, the adoption and approval of an amendment to the 2000 Plan increasing the shares available for issuance and sale thereunder from an aggregate of three million two-hundred thousand (3,200,000) to an aggregate of four million two-hundred thousand (4,200,000) and any arrangements in connection therewith, (g) resolutions of the Compensation Committee of the Board of Directors of the Company adopted on March 27, 2008 and resolutions of the Board of Directors of the Company adopted on July 2, 2008, as certified by the Secretary of the Company as being complete, accurate, and in effect, relating to, among other things, the adoption and approval of an amendment to the 2000 Plan increasing the shares available for issuance and sale

 



 

thereunder from an aggregate of four million two-hundred thousand (4,200,000) to an aggregate of six million five-hundred thousand (6,500,000) and any arrangements in connection therewith, and to the filing of the Registration Statement and (h) the originals or copies certified to our satisfaction of such other records, documents, certificates, memoranda and other instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below.

 

In rendering this opinion, we have assumed: the genuineness and authenticity of all signatures on original documents; the authenticity of all documents submitted to us as originals; the conformity to originals of all documents submitted to us as copies; the accuracy, completeness and authenticity of certificates of public officials; and the due authorization, execution and delivery of all documents, where authorization, execution and delivery are prerequisites to the effectiveness of such documents.  We have also assumed: that all individuals executing and delivering documents in their individual capacities had the legal capacity to so execute and deliver.  This opinion letter is given, and all statements herein are made, in the context of the foregoing.

 

Our opinion is expressed only with respect to the federal laws of the United States of America and the General Corporation Law of the State of Delaware. We express no opinion as to whether the laws of any particular jurisdiction other than those identified above are applicable to the subject matter hereof.

 

On the basis of the foregoing, and in reliance thereon, we are of the opinion that the 2000 Plan Shares, when sold and issued in accordance with the 2000 Plan, and the Registration Statement and related Prospectus, will be validly issued, fully paid and nonassessable (except as to shares issued pursuant to certain deferred payment arrangements, which will be fully paid and nonassessable when such deferred payments are made in full).

 

This opinion letter has been prepared for your use in connection with the Registration Statement and speaks as of the date hereof.  We assume no obligation to advise you of any changes in the foregoing subsequent to the effectiveness of the Registration Statement.

 

We hereby consent to the filing of this opinion letter as Exhibit 5.1 to the Registration Statement.

 

[SIGNATURE PAGE FOLLOWS]

 



 

*************

 

Sincerely,

 

 

Cooley Godward Kronish LLP

 

Darren K. DeStefano

 


Exhibit 23.1

 

Reznick Group, P.C

Tel: (301) 652-9100

7700 Old Georgetown Road

Fax: (301) 652-1848

Suite 400

www.reznickgroup.com

Bethesda, MD 20814-6224

 

 

CONSENT OF REZNICK GROUP, P.C.

INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We consent to the incorporation by reference in the Registration Statement on Form S-8 of RegeneRx Biopharmaceuticals, Inc. of our report dated March 27, 2008, with respect to the financial statements of RegeneRx Biopharmaceuticals, Inc. for the year ended December 31, 2007 included in its Annual Report (Form 10-K) for the year ended December 31, 2007, filed with the Securities and Exchange Commission.

 

 

/s/ Reznick Group, P.C.

 

Bethesda, Maryland

July 10, 2008

 

Atlanta   ·   Baltimore   ·    Bethesda    ·    Charlotte    ·    Chicago   ·    Los Angeies    ·    Sacramento    ·    Tysons Cornor